secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-06-27T23:59:59+00:00
Accession:  0001193125-25-151393
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera prices $250.8M public offering of common stock and pre-funded warrants
-----------------------------------------------------------------------------

- Offering includes 5,044,500 shares at $44.00 and pre-funded warrants for 655,500 shares at $43.9999.
- Net proceeds estimated at $237.3M (or $272.7M if underwriters option for 855K shares exercised).
- Proceeds to advance preclinical/clinical degrader programs and for working capital.
- Existing cash plus offering proceeds expected to fund operations into mid 2028.
- Company also entered registration rights agreement with Baker, Atlas, and BVF affiliates for up to 27.96M resale shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525151393/0001193125-25-151393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525151393/d85382d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-151393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer